Introduction
At present despite the availability of numerous agents for the treatment of
dyslipidemia there is a large scope for expanding the market by improving
diagnosis and treatment of the dyslipidemic patients. However, for new agents,
gaining a secure foothold on the market will be challenging, and can be
improved through targeting niche patient populations and conducting outcome
trials.
Scope
- Assessment of the patient potential for developmental anti-dyslipidemia
agents over the period 2007-16
- Overview of the anti-dyslipidemia R&D pipeline, with detailed information
on the classes in development and comparator drugs
- Commercial analysis of key compounds in development regarding their
ability to take away market share from the currently available drugs
- Sales forecasts for key late-stage developmental anti-dyslipidemia agents
in the seven major markets to 2016
Report Highlights
Single-pill combinations have their appeal, but not for every market. SPCs
have had a rather low uptake, especially in Europe, due to lack of titration
flexibility and cost issues. This development will halt the progress of SPCs
onto the major markets and will limit their success, especially In Europe and
Japan.
Increased efficacy in HDL-C raising is the most important unmet need, but the
fiasco of torcetrapib will impede speedy launch of efficacious HDL-raising
agents, as the CETP inhibitors will have to prove both their safety and
efficacy in extensive trials that will delay their arrival to market.
The crowded antidyslipidemic market undergoing high genericization will make
it challenging for the developmental compounds to secure a share of the
market. In order to do so, the new developmental agent will need to offer a
major improvement or a major cost benefit.
Reasons to Purchase
- Understand the key factors that will contribute to the success of the next
generation of anti-dyslipidemia drugs
- View independent sales forecasts for products in late stage development
for therapy of dyslipidemia
- Analyze competitive environment at time of product launch
View Cart
